Seeking Alpha
 

Seattle Genetics, Inc. (SGEN)

- NASDAQ
  • Wed, Jan. 21, 9:45 AM
    • Seattle Genetics (SGEN +2.6%) will report Q4 and full-year results on February 10 after the close. The conference call will begin at 1:30 pm PT/4:30 pm ET.
    • Consensus views for Q4 and 2014 are losses of ($0.25) and ($0.66) on revenues of $68.4M and $280.9M, respectively.
    | Comment!
  • Mon, Jan. 12, 1:44 PM
    • Seattle Genetics (SGEN +5.4%) and Bristol-Myers Squibb (BMY +4.4%) enter into a clinical trial collaboration to evaluate the combination of SGEN's Adcetris (brentuximab vedotin) and BMY's Opdivo (nivolumab) in two Phase 1/2 trials, one in patients with relapsed or refractory Hodgkin lymphoma (HL) and the other in patients with relapsed or refractory B-cell and T-cell non-Hodgkin lymphomas (NHL), including diffuse large B-cell lymphoma (DLBCL).
    • The trials will commence this year. Additional details about the partnership are undisclosed.
    | 2 Comments
  • Dec. 8, 2014, 12:37 PM
    • Biotech investors are giving Seattle Genetics (SGEN -8.4%) the cold shoulder today on increased volume. It appears that all the love is being directed to the potential of competitors' PD-1 inhibitors in fighting cancer despite the company's presentations at the American Society of Hematology meeting of positive results for Adcetris (brentuximab vedotin), an antibody-drug conjugate directed to CD30 in Hodgkin lymphoma (HL).
    • Long-term data from a Phase 1 trial of Adcetris combined with AVD (adriamycin, vinblastine, dacarbazine) demonstrated a 100% overall survival rate at year three and 92% failure-free survival rate at year 3 in frontline HL.
    • Adcetris in combination with bendamustine as a second-line therapy demonstrated an objective response rate of 96% and a complete remission rate of 83% in patients with relapsed or refractory HL.
    • In a Phase 2 trial in previously untreated HL patients aged 60 and older, Adcetris showed a 93% objective response rate.
    • The company is collaborating with Takeda Pharmaceutical Co. (OTCPK:TKPHF) (OTCPK:TKPYY) on the development of the product.
    • Previously: Positive results in Adcetris Phase 3 label expansion trial (Sept. 29, 2014)
    • PD-1 inhibitor-related tickers: (BMY +0.2%)(FPRX +4.8%)(MRK -0.2%)(CELG +4.2%)(OTCQX:RHHBY -0.5%)(AZN -0.6%)
    | 1 Comment
  • Oct. 30, 2014, 6:29 PM
    • Seattle Genetics (NASDAQ:SGEN) now expects full-year U.S./Canada Adcetris net product sales of $172M-$177M, better than prior guidance of $160M-$170M. Collaboration revenue (also better than expected) is now forecast to total $64M-$68M.
    • Q3 Adcetris net sales +32% Y/Y to $48.2M. Collaboration revenue -33% to $19.5M. Costs/expenses -3% to $91.5M.
    • SGEN +3.4% AH. Q3 results, PR
    | Comment!
  • Oct. 30, 2014, 4:15 PM
    • Seattle Genetics (NASDAQ:SGEN): Q3 EPS of -$0.13 beats by $0.11.
    • Revenue of $75.85M (+6.9% Y/Y) beats by $8.93M.
    • Shares +3.55%.
    • Press Release
    | Comment!
  • Oct. 14, 2014, 9:29 AM
    • Seattle Genetics (NASDAQ:SGEN) will report Q3 results on October 30 after the close. The conference call will begin at 1:30 pm PT/4:30 pm ET.
    • Consensus view is a loss of ($0.24) per share on revenues of $67M.
    | Comment!
  • Sep. 29, 2014, 8:08 AM
    • Seattle Genetics (NASDAQ:SGEN) and Takeda Pharmaceutical Co. announce positive results from a 329-patient Phase 3 clinical trial evaluating the safety and efficacy of Adcetris (brentuximab vedotin) as consolidation therapy immediately following an autologous stem cell transplantation (ASCT) in patients with Hodgkin lymphoma (HL).
    • The study met its primary endpoint of a statistically significant improvement in progression-free survival (PFS) compared to placebo. PFS improved 75% as assessed after a minimum of two years post initiation of treatment by an independent central review committee.
    • A pre-specified interim analysis of overall survival (OS) showed no statistically significant difference between the treatment arms. Patients in both cohorts with HL progression received a variety of subsequent therapies. Most in the placebo group received Adcetris after progression. A further analysis of OS is planned for 2016.
    • Adcetris is approved in over 45 countries for the treatment of relapsed HL and systemic anaplastic large cell lymphoma.
    | 5 Comments
  • Sep. 26, 2014, 5:37 PM
    | Comment!
  • Sep. 26, 2014, 4:44 PM
    • Seattle Genetics (NASDAQ:SGEN) will hold a conference call and webcast on Monday, September 29, 2014 at 5:30 am PT to discuss top-line results from the AETHERA Phase 3 clinical trial evaluating the safety and efficacy of Adcetris (brentuximab vedotin) in patients with Hodgkin lymphoma at risk of relapse following autologous stem cell transplant.
    | Comment!
  • Sep. 10, 2014, 10:21 AM
    • Seattle Genetics (SGEN +1.8%) and Denmark-based Genmab A/S collaborate on an antibody-drug conjugate for the potential treatment of solid tumors. Under the terms of the agreement, Genmab will pay SGEN an upfront fee of $11M for the exclusive rights to use its auristatin-based ADC technology with Genmab's HuMax-AXL antibody (expressed in multiple types of solid cancers). SGEN is eligible to receive up to $200M in potential milestone payments and mid-to-high single-digit royalties on net worldwide sales of any resulting products.
    • Prior to the start of a Phase 3 clinical trial, SGEN has the option of increasing the royalties to double digits in exchange for a reduction in milestone payments.
    • Genmab fully controls development and commercialization activities.
    | Comment!
  • Aug. 22, 2014, 5:36 PM
    | 2 Comments
  • Aug. 4, 2014, 12:05 PM
    | Comment!
  • Jul. 31, 2014, 4:53 PM
    • Seattle Genetics (SGEN -1.9%) Q2 results: Total Revenues: $68.3M (-7.2%); Operating Expenses: $86.0M (+6.7%); Operating Loss: ($17.6M) (-151.4%); Net Loss: ($17.6M) (-155.1%); Loss Per Share: ($0.14) (-133.3%); Quick Assets: $349.2M (-6.7%).
    • 2014 Guidance: Adcetris product sales in U.S. and Canada: $160M - 170M; R&D expenses: $235M - 250M.
    | Comment!
  • Jul. 31, 2014, 4:06 PM
    • Seattle Genetics (NASDAQ:SGEN): Q2 EPS of -$0.14 beats by $0.09.
    • Revenue of $68.31M (-7.1% Y/Y) beats by $3.27M.
    • Press Release
    | Comment!
  • Jul. 3, 2014, 3:07 PM
     
    • Top gainers, as of 2:45 p.m.: VRS +5.5%. PXLW +4.1%. SGEN +2.6%. ACHN +2.5%. JDST +2.3%.
    • Top losers, as of 2:45 p.m.: USU -9.1%. NBR -3.8%. SVM -3.3%. NG -3.0%. MUX -2.8%.
    | Comment!
  • May. 1, 2014, 9:29 PM
    • Total revenues: $68.3M (+19.2%): product sales: $38.7M (+14.2%), collab/license: $16.9M (-19.5%), royalties: $12.7M (+429%).
    • Loss from operations: $16.4M.
    • Net loss: $16.3M.
    • Quick assets (ex-A/R) at quarter end: $355.4M (-5%).
    • Q2 revenue estimate: $64.5M.
    • 2014 and 2015 revenue estimates are $263.2M and $331M, respectively.
    • (SGEN +1%)
    | Comment!
SGEN vs. ETF Alternatives
Company Description
Seattle Genetics Inc is a biotechnology company. It develops and commercializes monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease.
Sector: Healthcare
Industry: Biotechnology
Country: United States